Weight Loss Associated with Cholinesterase Inhibitors in Individuals with Dementia in a National Healthcare System

Journal of the American Geriatrics Society

Volumn 63, Issue 8, 2015, Pages 1512-1518

  Sheffrin, Meera ^a   Miao, Yinghui ^a   Boscardin, W John ^a,b   Steinman, Michael A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cholinesterase inhibitors; dementia; weight loss

Indexed keywords

AMLODIPINE; CHOLINESTERASE INHIBITOR; DOCUSATE SODIUM; DONEPEZIL; GALANTAMINE; HYDROCHLOROTHIAZIDE; OMEPRAZOLE; RIVASTIGMINE; SIMVASTATIN; TACRINE;

AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; ICD-9; MALE; PRESCRIPTION; PRIMARY MEDICAL CARE; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; WEIGHT CHANGE; WEIGHT REDUCTION; BODY WEIGHT; CLINICAL TRIAL; DRUG EFFECTS; EPIDEMIOLOGY; FOLLOW UP; INCIDENCE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; UNITED STATES;

AGED; BODY WEIGHT; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES; UNITED STATES; WEIGHT LOSS;

EID: 84939571694     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13511     Document Type: Article

References (32)

1. Wilkinson D, Doody R, Helme R, et al., Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology 2003; 61: 479-486.
2. Birks J,. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006: CD005593.
3. Doody RS, Stevens JC, Beck C, et al., Practice parameter: Management of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-1166.
4. Qaseem A, Snow V, Cross JT Jr, et al., Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148: 370-378.
5. Wallace JI, Schwartz RS, LaCroix AZ, et al., Involuntary weight loss in older outpatients: Incidence and clinical significance. J Am Geriatr Soc 1995; 43: 329-337.
6. Knudtson MD, Klein BE, Klein R, et al., Associations with weight loss and subsequent mortality risk. Ann Epidemiol 2005; 15: 483-491.
7. Rogers SL, Farlow MR, Doody RS, et al., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
8. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al., Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. BMJ 2005; 331: 321-327.
9. Schoenmaker N, Van Gool WA,. The age gap between patients in clinical studies and in the general population: A pitfall for dementia research. Lancet Neurol 2004; 3: 627-630.
10. St Germaine-Smith C, Metcalfe A, Pringsheim T, et al., Recommendations for optimal ICD codes to study neurologic conditions: A systematic review. Neurology 2012; 79: 1049-1055.
11. Martens PJ, Fransoo R, Burland E, et al., Prevalence of mental illness and its impact on the use of home care and nursing homes: A population-based study of older adults in Manitoba. Can J Psychiatry 2007; 52: 581-590.
12. Steinman MA, Lee SJ, John Boscardin W, et al., Patterns of multimorbidity in elderly veterans. J Am Geriatr Soc 2012; 60: 1872-1880.
13. Das SR, Kinsinger LS, Yancy WS Jr, et al., Obesity prevalence among veterans at Veterans Affairs medical facilities. Am J Prev Med 2005; 28: 291-294.
14. Alibhai SM, Greenwood C, Payette H,. An approach to the management of unintentional weight loss in elderly people. Can Med Assoc J 2005; 172: 773-780.
15. Wedick NM, Barrett-Connor E, Knoke JD, et al., The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: The Rancho Bernardo Study. J Am Geriatr Soci 2002; 50: 1810-1815.
16. Payette H, Coulombe C, Boutier V, et al., Nutrition risk factors for institutionalization in a free-living functionally dependent elderly population. J Clin Epidemiol 2000; 53: 579-587.
17. Mori E, Ikeda M, Kosaka K,. Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial. Ann Neurol 2012; 72: 41-52.
18. Ikeda M, Mori E, Kosaka K, et al., Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: Results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord 2013; 36: 229-241.
19. Farlow M, Veloso F, Moline M, et al., Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurol 2011; 11: 57.
20. Dubois B, Tolosa E, Katzenschlager R, et al., Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study. Mov Disord 2012; 27: 1230-1238.
21. Roman GC, Salloway S, Black SE, et al., Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: Differential effects by hippocampal size. Stroke 2010; 41: 1213-1221.
22. Wilkinson D, Roman G, Salloway S, et al., The long-term efficacy and tolerability of donepezil in patients with vascular dementia. Int J Geriatr Psychiatry 2010; 25: 305-313.
23. Black S, Roman GC, Geldmacher DS, et al., Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-2330.
24. Dichgans M, Markus HS, Salloway S, et al., Donepezil in patients with subcortical vascular cognitive impairment: A randomised double-blind trial in CADASIL. Lancet Neurol 2008; 7: 310-318.
25. Erkinjuntti T, Kurz A, Gauthier S, et al., Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002; 359: 1283-1290.
26. Hager K, Baseman AS, Nye JS, et al., Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Neuropsychiatr Dis Treat 2014; 10: 391-401.
27. Auchus AP, Brashear HR, Salloway S, et al., Galantamine treatment of vascular dementia: A randomized trial. Neurology 2007; 69: 448-458.
28. McKeith I, Del Ser T, Spano P, et al., Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036.
29. Emre M, Aarsland D, Albanese A, et al., Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
30. Ballard C, Sauter M, Scheltens P, et al., Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: The Vantage Study. Curr Med Res Opin 2008; 24: 2561-2574.
31. Droogsma E, van Asselt DZ, van Steijn JH, et al., Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia. J Nutr Health Aging 2013; 17: 461-465.
32. Uchiyama T, Chess-Williams R,. Muscarinic receptor subtypes of the bladder and gastrointestinal tract. J Smooth Muscle Res 2004; 40: 237-247.